Evidence map›Paper›PMID 22308025›Full record

ArticleThe Journal of biological chemistry2012

Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor β (TGF-β1) signaling axis.

Eduardo Mascareno, Josephine Galatioto, Inna Rozenberg, Louis Salciccioli, Haroon Kamran, Jason M Lazar, Fang Liu, Thierry Pedrazzini, M A Q Siddiqui

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. BET-ting on chromatin-based therapeutics for heart failure.Journal of molecular and cellular cardiology · 2014
    Review
  10. Lead optimization of HMBA to develop potent HEXIM1 inducers.Bioorganic & medicinal chemistry letters · 2014
    Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Eduardo MascarenoDepartment of Cell Biology, Center for Cardiovascular and Muscle Research, State University of New York Downstate Medical Center, Brooklyn, New York 11203, USA.
Josephine Galatioto
Inna Rozenberg
Louis Salciccioli
Haroon Kamran
Jason M Lazar
Fang Liu
Thierry Pedrazzini
M A Q Siddiqui
State University of New York · USRutgers, The State University of New Jersey · USSUNY Downstate Health Sciences University · USUniversity of Lausanne · CH

Funding

Jak/Stat Signaling Pathway in Myocardial HypertrophyR01HL073399 · NHLBI · SUNY DOWNSTATE MEDICAL CENTER · PI SIDDIQUI, MAQ A · 2003 to 2006
$1.3M
NHLBI NIH HHS HL073399NHLBI NIH HHS R01 HL073399
6 · The paper itself

Abstract

It is well known that the renin-angiotensin system contributes to left ventricular hypertrophy and fibrosis, a major determinant of myocardial stiffness. TGF-β1 and renin-angiotensin system signaling alters the fibroblast phenotype by promoting its differentiation into morphologically distinct pathological myofibroblasts, which potentiates collagen synthesis and fibrosis and causes enhanced extracellular matrix deposition. However, the atrial natriuretic peptide, which is induced during left ventricular hypertrophy, plays an anti-fibrogenic and anti-hypertrophic role by blocking, among others, the TGF-β-induced nuclear localization of Smads. It is not clear how the hypertrophic and fibrotic responses are transcriptionally regulated. CLP-1, the mouse homolog of human hexamethylene bis-acetamide inducible-1 (HEXIM-1), regulates the pTEFb activity via direct association with pTEFb causing inhibition of the Cdk9-mediated serine 2 phosphorylation in the carboxyl-terminal domain of RNA polymerase II. It was recently reported that the serine kinase activity of Cdk9 not only targets RNA polymerase II but also the conserved serine residues of the polylinker region in Smad3, suggesting that CLP-1-mediated changes in pTEFb activity may trigger Cdk9-dependent Smad3 signaling that can modulate collagen expression and fibrosis. In this study, we evaluated the role of CLP-1 in vivo in induction of left ventricular hypertrophy in angiotensinogen-overexpressing transgenic mice harboring CLP-1 heterozygosity. We observed that introduction of CLP-1 haplodeficiency in the transgenic α-myosin heavy chain-angiotensinogen mice causes prominent changes in hypertrophic and fibrotic responses accompanied by augmentation of Smad3/Stat3 signaling. Together, our findings underscore the critical role of CLP-1 in remodeling of the genetic response during hypertrophy and fibrosis.

Indexed as

Angiotensin IIAngiotensinogenAnimalsCardiomegalyExtracellular MatrixFibroblastsFibrosisHeterozygoteMaleMiceMice, Inbred C57BLMice, TransgenicMyosin Heavy ChainsRNA-Binding ProteinsSignal TransductionSmad3 ProteinAngiotensin IIAngiotensinogenHexim1 protein, mouseMyosin Heavy ChainsRNA-Binding ProteinsSmad3 ProteinSmad3 protein, mouseStat3 protein, mouseSTAT3 Transcription FactorTranscription FactorsTransforming Growth Factor beta1

Identifiers

PMID22308025
PMCPMC3339995
OpenAlexW2106698189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.